Related Experiment Videos
[Clinical study of SY5555 dry syrup in the pediatric field]
1Department of Pediatrics, Kobe City General Hospital.
Insights
SY5555 dry syrup demonstrated 100% clinical efficacy in pediatric patients with bacterial infections. This new oral antibiotic showed a high bacteriological eradication rate and no significant side effects, proving its utility in pediatrics.
Area of Science:
- Pediatric infectious diseases
- Clinical pharmacology
- Microbiology
Background:
- Bacterial infections are common in pediatric patients.
- There is a need for effective and safe oral antibiotics in pediatric care.
- SY5555 is a novel dry syrup formulation for pediatric use.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of SY5555 dry syrup in pediatric patients.
- To assess the bacteriological eradication rates of SY5555 against common pediatric pathogens.
- To determine patient compliance with SY5555 treatment.
Main Methods:
- A clinical study was conducted on 6 pediatric patients diagnosed with pharyngitis, tonsillitis, lacunar tonsillitis, impetigo contagiosa, or scarlet fever.
- SY5555 was administered at a daily dose of 14.5-29.0 mg/kg, divided into three dosages.
- Bacterial cultures were identified, and eradication rates were calculated. Side effects and patient compliance were monitored.
Main Results:
- SY5555 achieved an excellent or good clinical outcome in all 6 patients, resulting in a 100% clinical efficacy rate.
- The bacteriological eradication rate was 83.3%, with 5 out of 6 bacterial strains (Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus) eradicated.
- No significant side effects were observed, with only one case showing an elevated eosinophil count. Patient compliance was generally good.
Conclusions:
- SY5555 dry syrup is a highly effective and safe oral antibiotic for treating bacterial infections in pediatric patients.
- The drug demonstrated a high bacteriological eradication rate and good patient compliance.
- SY5555 is considered a valuable new therapeutic option in pediatric infectious disease management.
Abstract:
SY5555 dry syrup (powder to be dissolved before use) was clinically used in pediatric patients. The following results were obtained: 1. The subjects were 6 pediatric patients including 1 case each with pharyngitis, tonsillitis, lacunar tonsillitis and impetigo contagiosa and 2 cases with scarlet fever. The drug was administered at a daily dose of 14.5-29.0 mg/kg divided into 3 dosages. The clinical results were excellent in 5 cases and good in 1 case with an efficacy rate of 100%. 2. Identified bacteria included 3 strains of Haemophilus influenzae, 2 strains of Streptococcus pyogenes and 1 strain of Staphylococcus aureus. Five strains were eradicated but 1 strain still remained with an bacteriological eradication rate of 83.3%. 3. No side effects were observed throughout the study period. In laboratory test results, elevated eosinophil count was observed in only 1 case. 4. Patients' compliance was good in general. 5. Based on the results mentioned above, the drug was considered to be a useful new oral antibiotic in the pediatric field.